MediBeacon(R) Transdermal GFR System Receives FDA Approval to Assess Kidney Function

(NYSE:VATE), Transdermal GFR System (TGFR) is a first-in-kind product for point of care assessment of kidney function in patients with normal or impaired renal function The transdermal GFR (tGFR) methodology has been designed to be effective across the adult population without input of age, weight, sex, gender, race, or ethnicity More than 800 million people […]

Shareholders that Lost Money on Applied Therapeutics, Inc. (APLT) Should Contact Levi & Korsinsky about Pending Class Action – APLT

NEW YORK, NY / ACCESS Newswire / January 17, 2025 / If you suffered a loss on your Applied Therapeutics, Inc. (NASDAQ:APLT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/applied-therapeutics-inc-lawsuit-submission-form?prid=123560&wire=1 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or

Levi & Korsinsky Reminds Sun Communities, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025 – SUI

NEW YORK, NY / ACCESS Newswire / January 17, 2025 / If you suffered a loss on your Sun Communities, Inc. (NYSE:SUI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sun-communities-inc-lawsuit-submission-form?prid=123559&wire=1 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or

Uniti Group Inc. Announces Pricing of $589 Million Fiber Securitization Notes Offering

(NASDAQ:UNIT), LITTLE ROCK, Ark., Jan. 17, 2025 (GLOBE NEWSWIRE) — Uniti Group Inc. (the “Company,” “Uniti,” or “we”) (Nasdaq: UNIT) today announced that Uniti Fiber ABS Issuer LLC and Uniti Fiber TRS Issuer LLC, limited-purpose, bankruptcy remote subsidiaries of Uniti (collectively, the “Issuers”), have priced their offering of $589,000,000 aggregate principal amount of secured fiber

Encore Data Products to Unveil Innovative Learning Tools at TCEA 2025

Lafayette, Jan. 17, 2025 (GLOBE NEWSWIRE) — Lafayette, Colorado – Encore Data Products is set to showcase its wide array of audio and technology solutions at the Texas Computer Education Association (TCEA) convention in February 2025. This event is a major attraction for educators who are looking to explore new ways of teaching through technology.

Light & Wonder, Inc. Announcement: If You Have Suffered Losses in Light & Wonder, Inc. (NASDAQ: LNW), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

(NASDAQ:LNW), NEW YORK, Jan. 17, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Light & Wonder, Inc. (NASDAQ: LNW) resulting from allegations that Light & Wonder may have issued materially misleading business information to the investing public. SO

RTO DEADLINE ALERT: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Rentokil Initial plc Investors to Secure Counsel Before Important January 27 Deadline in Securities Class Action – RTO

NEW YORK, NY / ACCESS Newswire / January 17, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Shares ("ADS") of Rentokil Initial plc (NYSE:RTO) between December 1, 2023 and September 10, 2024, both dates inclusive (the "Class Period"), of the important January 27, 2025 lead plaintiff

Advanced Bifurcation Systems Inc. Secures $20.8 Million in Financing and Expands Board of Directors

Advanced Bifurcation Systems Inc. (ABS), a leader in innovative solutions for bifurcation lesions in coronary angioplasty, announces the successful closure of a $20.8 million Simple Agreement for Future Equity (SAFE) financing round. The round was oversubscribed, reflecting strong demand from high-net-worth individuals and family offices across the United States and internationally. https://mma.prnewswire.com/media/2574714/ABS_Logo.jpg The company is

MediBeacon® Transdermal GFR System Receives FDA Approval to Assess Kidney Function

— Transdermal GFR System (TGFR) is a first-in-kind product for point of care assessment of kidney function in patients with normal or impaired renal function. — The transdermal GFR (tGFR) methodology has been designed to be effective across the adult population without input of age, weight, sex, gender, race, or ethnicity. — More than 800

Scroll to Top